<DOC>
	<DOC>NCT02516527</DOC>
	<brief_summary>The purpose of this study is to determine whether ipilimumab is effective in the treatment of select advanced (unresectable, metastatic, or recurrent) solid tumors in Chinese subjects.</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Subjects with the following advanced solid tumors; metastatic or recurrent Must have measurable/nonmeasurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria. Subjects have ability to comply with treatment, procedures and pharmacokinetics (PK) sample collection and the required study followup Chinese women and men, ages 18 years or older Subjects with brain metastases are excluded unless clinically stable for more than 4 weeks at the time of randomization as determined by the investigator Subjects with ocular melanoma are excluded Any other malignancy from which the subject has been free of disease for less than two years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix History of, or currently active, autoimmune diseases, including but not limited to inflammatory bowel disease, rheumatoid arthritis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (eg, GuillainBarre syndrome). Vitiligo is not excluded Any current or history of immunodeficiency, splenectomy, or splenic radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>